Pantop%2525252525252525252520d

# Pantoprazole ## Overview Pantoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion by inhibiting the H+/K+-ATPase enzyme system in the gastric parietal cell. It is available in oral (delayed-release tablets, suspension) and intravenous formulations. ## Primary Indications * Treatment of erosive esophagitis (associated with GERD). * Maintenance of healing of erosive esophagitis. * Pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome). * Short-term treatment of GERD symptoms. ## Adult Dosing * **Erosive esophagitis:** 40 mg PO or IV once daily for up to 8 weeks. * **Maintenance of healing:** 40 mg PO once daily. * **Hypersecretory conditions:** 40 mg PO twice daily (up to 240 mg/day required in some cases; adjust based on patient response). * **GERD symptoms:** 20–40 mg PO once daily. ## Pediatric Dosing * **GERD (5 years and older):** * 15 kg to <40 kg: 20 mg PO once daily for up to 8 weeks. * 40 kg or greater: 40 mg PO once daily for up to 8 weeks. * *Note: IV use in pediatrics is not standard and lacks robust safety data. Dosing outside these parameters should follow local institutional protocols.* ## Dose Adjustments * **Renal Impairment:** No dosage adjustment indicated. * **Hepatic Impairment:** No initial dosage adjustment. For severe impairment, monitor for safety. Maximum doses in severe liver disease may require limitation; specific titration depends on clinical judgment and local protocol. ## Contraindications * Hypersensitivity to pantoprazole or any substituted benzimidazole (e.g., omeprazole, lansoprazole). * Concurrent use with rilpivirine-containing products. ## Adverse Effects * **Common:** Headache, diarrhea, nausea, abdominal pain, flatulence. * **Serious:** *Clostridioides difficile*-associated diarrhea, hypomagnesemia, vitamin B12 deficiency (with long-term use), acute interstitial nephritis, cutaneous lupus erythematosus, bone fractures (risk associated with long-term, high-dose use). ## Key Drug Interactions * **pH-dependent drugs:** May decrease the absorption of drugs requiring acidic gastric pH (e.g., atazanavir, ketoconazole, iron salts, mycophenolate mofetil). * **Methotrexate:** PPIs may increase serum levels of methotrexate. * **Warfarin:** Monitor INR frequently; occasional reports of increased INR/prothrombin time. ## Monitoring * Monitor for signs of *C. difficile* (persistent watery diarrhea). * Check serum magnesium in patients on long-term therapy or taking concomitant digoxin/diuretics. * Assess for clinical improvement; limit long-term use to the lowest effective dose. ## Clinical Pearls * **Administration:** Tablets should be swallowed whole; do not crush or chew. IV administration should be a 15-minute infusion or direct injection over at least 2 minutes. * **Bioavailability:** Oral bioavailability is relatively high (~77%) and remains consistent with multiple dosing. * **Tapering:** Long-term PPI users may experience rebound acid hypersecretion upon discontinuation; consider tapering the dose if therapy exceeds several months. * **Safety:** Always evaluate for the ongoing necessity of PPI therapy, as many patients remain on these agents without a clear long-term indication. *** *Disclaimer: This information is for educational purposes only. Always consult current institutional guidelines, local formularies, and the most recent prescribing information (package insert) before making clinical decisions.*